31 results about "Nasal polyps" patented technology

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

This disclosure provides a method, device, and storage medium for identifying the spatial aggregation features of immune cells in nasal polyps, relating to the field of data processing technology. The implementation scheme is as follows: A nasal polyp pathological slide is segmented into multiple pathological sub-images; positive immune cells are identified in each pathological sub-image to obtain the sub-image coordinates of each positive immune cell in each pathological sub-image; based on the positional information of each pathological sub-image on the nasal polyp pathological slide, the sub-image coordinates of each positive immune cell in each pathological sub-image are mapped onto the nasal polyp pathological slide to obtain the full-map coordinates of each positive immune cell in the nasal polyp pathological slide; based on the full-map coordinates of each positive immune cell in the nasal polyp pathological slide, cluster analysis is performed on the positive immune cells in the nasal polyp pathological slide to obtain the spatial aggregation features of immune cells in the nasal polyp tissue in the nasal polyp pathological slide. This improves the accuracy of the spatial aggregation features of immune cells in nasal polyps.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

A set of antisense oligonucleotides specifically inhibiting thymic stromal lymphopoietin and the use thereof. The antisense oligonucleotide molecules have a length of 16-20 bases. The antisense oligonucleotide molecules have the following use: (1) in the preparation of a preparation for inhibiting the expression level of thymic stromal lymphopoietin; or (2) in the treatment of asthma, atopic dermatitis, chronic obstructive pulmonary disease, sinusitis, and nasal polyps.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention provides a nasal polyp pathological section image recognition method and device, electronic equipment and a storage medium, and relates to the technical field of artificial intelligence and data processing. According to the implementation scheme, a domain generalization model is adopted to perform domain generalization on a nasal polyp pathological section image under a first visual field of a first detection object, and a nasal polyp pathological domain invariant feature map is obtained; a cell classification model and a tissue region segmentation model are adopted to carry out cell category classification and tissue region segmentation on the nasal polyp pathological domain invariant feature map to obtain the cell type of each cell in the nasal polyp pathological domain invariant feature map, an epithelial region, a blood vessel region and a gland region, and statistics is carried out according to the cell type, the epithelial region, the blood vessel region and the gland region. And determining the nasal polyp inflammation type of the first detection object according to a statistical result. Therefore, the recognition generalization and accuracy of the nasal polyp inflammation type are improved.

The invention relates to a traditional Chinese medicine composition for treating rhinitis and belongs to the technical field of traditional Chinese medicines. The composition is prepared from traditional Chinese medicinal materials such as centipeda minima, phryma leptostachya, cocklebur fruit, mint, asarum, camphor and the like through gradient crushing to obtain micron-sized powder with D90 smaller than or equal to 150 microns, and is prepared through low-temperature drying, volatile oil directional extraction and honey shaping processes. Aiming at acute and chronic rhinitis, allergic rhinitis, nasosinusitis, nasal polyp and other diseases, the composition provided by the invention realizes simultaneous treatment of principal and subordinate symptoms through anti-inflammatory and detumescence, immunity regulation, mucous membrane repair and other multi-target effects. According to the technology, through component optimization, process innovation and intelligent drug delivery design, the problems that a traditional Chinese medicine preparation is fuzzy in component, low in absorption rate, high in recurrence rate and the like are solved, and a safe, efficient and convenient new choice is provided for rhinitis treatment.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

The invention discloses a traditional Chinese medicine composition for treating rhinitis and a preparation method thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine raw materials and functional auxiliary materials, wherein the traditional Chinese medicine raw materials comprise the following medicinal materials in percentage by weight: 12% of biond magnolia flower, 12% of small centipeda herb, 15% of dwarf lilyturf tuber, 3% of wild chrysanthemum flower, 3% of dahurian angelica root, 3% of dandelion, 3% of manchurian wildginger, 3% of cocklebur fruit, 8% of common burreed rhizome, 8% of curcuma zedoary, 10% of red-rooted salvia root, 6% of szechuan lovage rhizome and 6% of thunberg fritillary bulb; the functional auxiliary materials comprise the following raw materials in percentage by weight: 0.4% of cellulase, 0.2% of pectinase, 1.2% of carbomer, 0.8% of poloxamer, 0.1% of glycyrrhetinic acid, 0.05% of limonene, 5.24% of chitosan-sodium alginate and 0.01% of an anti-VEGF antibody. According to the application, a nasal polyp targeting component is added, so that the dual effects of dredging orifices, resisting inflammation (rhinitis) and resisting fiber (nasal polyp) are realized; the clinical value is higher than that of single rhinitis treatment; plant cell walls are destroyed by adopting composite enzymolysis, and fat-soluble, water-soluble and volatile oil active ingredients are synchronously extracted in combination with supercritical CO2 extraction; the mucous membrane stimulation risk caused by impurities is reduced.

This invention relates to a group of antisense oligonucleotides that specifically inhibit thymic stromal lymphopoietin and their applications. The antisense oligonucleotide molecules are 16-20 bases in length. This invention also relates to the following applications of the antisense oligonucleotide molecules (ASO): (1) preparing preparations that inhibit the expression of thymic stromal lymphopoietin; (2) treating asthma, atopic dermatitis, COPD, sinusitis and nasal polyps.

The invention provides a nasal polyp automatic grading model training method, a scoring method, a system and equipment, and relates to the technical field of image analysis. In order to solve the problem that automatic grading of nasal polyp of a chronic sinusitis patient is difficult to realize in the prior art, an endoscopic image set containing different grades of nasal polyp score marking information is constructed based on nasal endoscopic image data of the patient, and a preset target detection model is trained by using the image set, so that the classification of the nasal polyp of the chronic sinusitis patient is realized. Therefore, the preset target detection model can directly learn and internalize the international standard of nasal polyp grade scoring, and then the preset target detection model can stably learn the nasal endoscope characteristics covering each scoring grade through the full-process training of data enhancement, cross validation and hyper-parameter tuning, so that the accuracy of the nasal endoscopy is improved. And the output nasal polyp grade score has both automation and accuracy, so that the core technical bottleneck of automatic nasal polyp grading under the endoscope is solved.

This invention discloses a method for constructing a sinusitis regulation analysis model based on nasal polyp cell inhibition data, belonging to the field of CRSwNP disease analysis technology. The method includes the following steps: collecting Lund-Kennedy scores and corresponding nasal polyp cell inhibition data from CRSwNP patients to obtain raw sample data; screening the raw sample data to remove unqualified raw sample data from CRSwNP patients to obtain standard sample data; performing index preprocessing based on the standard sample data and obtaining the optimal lag order to obtain reference sample data; constructing an LK analysis prediction model based on the reference sample data and analyzing and predicting the Lund-Kennedy scores of CRSwNP patients. This invention addresses the problem that existing CRSwNP disease analysis technologies cannot provide clinicians with objective and reliable analytical and predictive tools when analyzing and predicting the Lund-Kennedy scores of CRSwNP patients, thus failing to help clinicians reliably predict the disease progression of CRSwNP patients during treatment.

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.

IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof. 20 24 22 02 14 30 S ep 2 02 4 A B S T R A C T 2 0 2 4 2 2 0 2 1 4 3 0 2 0 2 4 S e p

The nasal polyp cutting knife comprises an outer tube, the outer tube is of a cavity structure, the inner diameter of the outer tube is gradually increased from the top end to the bottom end, a planing outer knife is arranged at the position, close to the top end, of the outer tube, an inner tube is inserted into the outer tube, the interior of the inner tube is of a cavity structure, and the inner diameter of the inner tube is gradually increased from the top end to the bottom end. An inner planing cutter matched with the outer planing cutter is arranged on the inner pipe, and an inner cutter left edge and an inner cutter right edge are arranged on the left side and the right side of the inner planing cutter respectively. The invention relates to the technical field of nasal polyp cutting knives, and has the beneficial effects that after a cutting blade is additionally arranged at the near end of a planing inner knife, the added tooth blade can effectively reduce the amount of polyp entering during negative pressure suction and increase the amount of cut polyp to be smaller and more crushed, the polyp is gradually thickened through a pipeline so as to avoid blockage, the thickness of an inner pipe is increased, and the cutting efficiency is improved. The nasal polyp can be conveniently sucked out through a gradually thickened pipeline under the condition that the nasal polyp is cut to be smaller and more broken.

The invention relates to the technical field of nasal disease treatment, in particular to a plant composition for treating nasal polyp and nasal gland hypertrophy, which is prepared from the following raw material medicines in parts by mass: 10 to 15 parts of flos magnoliae, 8 to 12 parts of radix angelicae, 10 to 20 parts of radix scutellariae, 15 to 25 parts of honeysuckle flower, 10 to 18 parts of fructus forsythiae, 5 to 10 parts of radix platycodonis, 3 to 8 parts of herba menthae, 10 to 20 parts of herba houttuyniae and 5 to 12 parts of herba centipedae. And the following active extraction components in parts by weight: 1-3 parts of bromelain, 0.5-2 parts of quercetin, 0.5-1.5 parts of curcumin and 1-4 parts of a frankincense serrata serrata extract. Nasal cavity inflammation and tissue edema are effectively relieved through a combined effect, firstly, flos magnoliae and radix angelicae in the formula can dissipate wind-cold, dredge nasal orifices and directly improve the ventilation function of the nasal cavity, meanwhile, radix scutellariae, honeysuckle and other medicinal materials clear away damp-heat toxin in the body through the effects of clearing away heat and drying dampness, inflammatory response is inhibited from the source, and the effect is remarkable. By matching with modern active ingredients such as bromelain and curcumin, the release of inflammatory mediators can be further blocked, and the capillary permeability is reduced.

The application discloses a method for stereoscopic reconstruction and visualization of nasal polyp tissue based on artificial intelligence recognition of continuous pathological sections, which comprises the following steps: strict continuous section of a reconstruction object; HE staining of the continuous sections; affine registration of the continuous pathological sections; one-by-one analysis of the registered continuous pathological sections; stacking according to the registration sequence, then processing, to obtain three-dimensional model data of the nasal polyp tissue structure; and visual rendering of the three-dimensional model data of the nasal polyp tissue structure, combined with a preliminary stereoscopic model, to obtain a final stereoscopic model of the nasal polyp tissue structure. The method can reconstruct and visualize the nasal polyp tissue, and can show the three-dimensional structure of the distribution characteristics of inflammatory cells and tissue structure of the nasal polyp in the spatial structure, so that the morphological structure content of the nasal polyp tissue is enriched, and morphological basis is provided for further exploring the occurrence and development mechanism of chronic rhinosinusitis with nasal polyps.

The application discloses a nasal secretion biomarker composition for diagnosing type 2 chronic rhinosinusitis with nasal polyps and application thereof, relates to the technical field of biological medicine, and the nasal secretion biomarker composition comprises glial cell-derived neurotrophic factor, cystatin 5, transforming growth factor beta 1 and monocyte chemoattractant protein 4. When the nasal secretion biomarker composition is used for diagnosing CRSwNP intrinsic type, nasal secretion is used as a detection sample, polyp biopsy is not needed, the nasal secretion biomarker composition is non-invasive, simple, convenient, has high sensitivity and specificity, can classify CRSwNP patients before operation without damaging mucosa, can predict the disease intrinsic type of the CRSwNP patient in advance and accurately, and is an ideal non-invasive method.

The present disclosure relates generally to methods of treating chronic rhinosinusitis with or without nasal polyps using antibodies specific for thymic stromal lymphopoietin (TSLP).

150 mg / mL omaszumab formulations for use in methods of treating one or more of the following: allergic asthma; chronic nasal-nasosinusitis accompanied by nasal polyp; chronic spontaneous urticaria; nasal polyp; food allergy; medium to severe persistent asthma in patients having a positive skin test or in vitro reactivity to perennial aerogenic allergens and symptoms inadequately controlled with inhaled corticosteroids wherein the omaszumab is administered subcutaneously by a syringe.

This disclosure provides a biomarker for prognostic purposes in patients with chronic sinusitis and nasal polyps, which contains a Tuft cell-specific gene or its encoded protein. This biomarker has been validated to have good sensitivity and specificity and can effectively predict the surgical prognosis of patients with chronic sinusitis and nasal polyps.

The invention discloses application of an ADAM8 gene and / or ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp and the medicine, and relates to the technical field of biological medicines. According to the application of the ADAM8 gene and / or the ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp, the ADAM8 gene and / or the ADAM8 protein are / is used as a treatment target. The research finds that the gene and protein expression level of ADAM8 are obviously up-regulated in ECRSwNP and NECRSwNP and are mainly distributed in inflammatory cells of epithelium and below the epithelium, which prompts that ADAM8 may be a key pathogenic factor in CRSwNP pathogenesis. By specifically inhibiting the activity of ADAM8, nasal polyp-like lesions can be remarkably relieved, infiltration of eosinophilic granulocytes, neutrophil granulocytes and other inflammatory cells can be reduced, key inflammatory signal pathways can be inhibited, collagen deposition and metal matrix protease expression can be reduced, then inflammatory response and a tissue remodeling process can be effectively relieved, and the application of ADAM8 in treatment of nasal polyp-like diseases can be promoted. The scientificity and clinical application prospect of the ADAM8 as a treatment target are verified.

The invention discloses an application of methylmalonyl coenzyme A mutase protein in preparation of a medicine for treating eosinophilic nasal polyp. The amino acid sequence of a small subunit PPA0595 of the methylmalonyl coenzyme A mutase protein is shown as SEQ ID NO: 1, and the amino acid sequence of a large subunit PPA0596 of the methylmalonyl coenzyme A mutase protein is shown as SEQ ID NO: 2. By inhibiting the phosphorylation level of nasal mucosa epithelial cells STAT3, eoxin-1 and eoxin-2 chemotactic factors of eoxin-1 and eoxin-2 are down-regulated, then infiltration of eoxin-1 is reduced, type II inflammatory reaction is relieved, the treatment effect on eoxin-1 and eoxin-2 is achieved, and a brand-new view angle and a brand-new target spot are provided for treatment of nasal polyp.

This disclosure provides a method, device, and storage medium for cutting nasal polyp pathological images based on mask images, relating to the field of data processing technology. The implementation scheme is as follows: The nasal polyp pathological slide is reduced in size based on a preset reduction ratio; the reduced nasal polyp pathological slide is segmented into nasal polyp tissue and background to obtain a masked pathological image; the masked pathological image is cut to obtain multiple first sub-masked pathological images; an integral operation is performed on each first sub-masked pathological image; based on the integral results of each first sub-masked pathological image, multiple second sub-masked pathological images are selected from the multiple first sub-masked pathological images; based on the coordinates of each second sub-masked pathological image in the masked pathological image, the mapping coordinates of each second sub-masked pathological image on the nasal polyp pathological slide are determined; based on the mapping coordinates of each second sub-masked pathological image on the nasal polyp pathological slide, the nasal polyp pathological slide is cut to obtain the target nasal polyp pathological slide. This improves the cutting efficiency of nasal polyp pathological slides.